v3.26.1
COMMITMENTS AND CONTINGENCIES (Details)
3 Months Ended 6 Months Ended
Dec. 20, 2024
Jul. 15, 2015
USD ($)
Jun. 30, 2026
USD ($)
Number
Director
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
Number
Director
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Commitments and Contingencies [Line Items]              
Number of pending or threatened lawsuits     0   0    
Operating lease costs     $ 5,454 $ 4,800 $ 10,988 $ 9,767  
Number of non audit committee chairs | Number     2   2    
Office space lease renewed term     1 year   1 year    
Licensed technology term.   20 years          
Annual royalty payment   5.00%          
Accrued royalties     $ 36,206   $ 36,206   $ 52,192
Royalty expense     16,773 $ 9,307 30,463 $ 22,679  
Percentage of royalty payments of net sales 4.00%            
Percentage of revenue 20.00%            
Charles Allen [Member]              
Commitments and Contingencies [Line Items]              
Cash compensation     2,000   2,000    
Piramal [Member]              
Commitments and Contingencies [Line Items]              
Purchase obligation     468,960   468,960    
Purchase obligation, around december 2026     228,960   228,960    
Purchase obligation, march 2027     240,000   240,000    
Paul Field [Member]              
Commitments and Contingencies [Line Items]              
Cash compensation     1,250   1,250    
US Government Sales [Member]              
Commitments and Contingencies [Line Items]              
Royalty expense   $ 35,000,000          
U.S. Army Agreement [Member]              
Commitments and Contingencies [Line Items]              
Royalty expense   $ 35,000,000          
Tufts MC Agreement [Member]              
Commitments and Contingencies [Line Items]              
Royalty expense         0    
Board of Directors Chairman [Member]              
Commitments and Contingencies [Line Items]              
Annual royalty payment   3.00%          
Board of Directors Chairman [Member] | Stephen Toovey [Member]              
Commitments and Contingencies [Line Items]              
Cash compensation     $ 11,250   $ 11,250    
Director [Member]              
Commitments and Contingencies [Line Items]              
Number of director nominees | Director     4   4    
Equity-based compensation awards term         annual    
Minimum [Member]              
Commitments and Contingencies [Line Items]              
Percentage of treatment of babesiosis 2.00%            
Maximum [Member]              
Commitments and Contingencies [Line Items]              
Percentage of treatment of babesiosis 10.00%            
IPO [Member]              
Commitments and Contingencies [Line Items]              
Payment     $ 10,000,000   $ 10,000,000